Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 306 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Five-Year Outcomes with CAR T Cell Therapy February 22, 2021 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 The link between Down syndrome and childhood leukaemia September 1, 2022 Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... December 7, 2021 Load more HOT NEWS Turning the Life Sciences Vision into reality Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... How Fatty Liver Disease Helps Cancer Thrive in the Liver T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast...
